^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PTCH1 mutation

    i
    Other names: PTC1, Patched Homolog 1, Protein Patched Homolog 1
    Entrez ID:
    5727
    Related biomarkers:
    Mutation
    CNA
    Fusion
    Others
    Apply
    SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors (NCT03434262)
    Phase 1
    St. Jude Children's Research Hospital
    Completed
    Last update posted :
    05/31/2024
    Initiation :
    03/05/2018
    Primary completion :
    09/30/2022
    Completion :
    05/24/2024
    PTCH1
    |
    PTCH1 mutation
    |
    Mekinist (trametinib) • gemcitabine • Kisqali (ribociclib) • Odomzo (sonidegib) • Neupogen (filgrastim)
    Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma (NCT03467789)
    Phase 1
    Case Comprehensive Cancer Center
    Active, not recruiting
    Last update posted :
    05/02/2024
    Initiation :
    10/01/2018
    Primary completion :
    09/01/2024
    Completion :
    09/01/2024
    PTCH1
    |
    PTCH1 mutation
    Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome (NCT06050122)
    Phase 3
    Sol-Gel Technologies, Ltd.
    Recruiting
    Last update posted :
    04/19/2024
    Initiation :
    03/17/2024
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    PTCH1
    |
    PTCH1 mutation
    |
    patidegib topical (IPI-926 topical)
    A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations (NCT05199584)
    Phase 2
    Endeavor Biomedicines, Inc.
    Active, not recruiting
    Last update posted :
    12/18/2023
    Initiation :
    05/24/2022
    Primary completion :
    05/01/2024
    Completion :
    05/01/2024
    PTCH1
    |
    PTCH1 mutation
    |
    taladegib (ENV 101)
    Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome) (NCT03703310)
    Phase 3
    PellePharm, Inc.
    Completed
    Last update posted :
    03/08/2021
    Initiation :
    02/19/2019
    Primary completion :
    12/28/2020
    Completion :
    12/28/2020
    PTCH1
    |
    PTCH1 mutation
    |
    patidegib topical (IPI-926 topical)
    Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face (NCT00489086)
    Phase 2
    UCSF Benioff Children's Hospital Oakland
    Completed
    Last update posted :
    10/29/2020
    Initiation :
    07/01/2004
    Primary completion :
    06/01/2012
    Completion :
    06/01/2012
    PTCH1
    |
    PTCH1 mutation
    Blue vs Red Light During Levulan Based Photodynamic Therapy in Patients With Basal Cell Nevus Syndrome (NCT02157623)
    Phase N/A
    Edward Maytin, MD, PhD
    Completed
    Last update posted :
    07/30/2020
    Initiation :
    02/01/2016
    Primary completion :
    09/01/2016
    Completion :
    12/01/2016
    PTCH1
    |
    PTCH1 mutation
    Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients (NCT02762084)
    Phase 2
    PellePharm, Inc.
    Completed
    Last update posted :
    07/23/2020
    Initiation :
    06/06/2016
    Primary completion :
    04/24/2017
    Completion :
    04/24/2017
    PTCH1 • GLI1
    |
    PTCH1 mutation
    |
    patidegib topical (IPI-926 topical)
    Photodynamic Therapy Using Blue Light or Red Light in Treating Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome (NCT02258243)
    Phase 2
    Case Comprehensive Cancer Center
    Active, not recruiting
    Last update posted :
    11/07/2016
    Initiation :
    12/01/2015
    Primary completion :
    10/01/2016
    Completion :
    12/01/2017
    PTCH1
    |
    PTCH1 mutation
    Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back (NCT00783965)
    Phase 2
    UCSF Benioff Children's Hospital Oakland
    Completed
    Last update posted :
    02/11/2016
    Initiation :
    07/01/2004
    Primary completion :
    06/01/2012
    Completion :
    01/01/2014
    PTCH1
    |
    PTCH1 mutation